Nitisinone Dipharma (Nitisinone)

Nitisinone blocks the enzyme 4‑hydroxyphenylpyruvate dioxygenase (HPPD) in the tyrosine degradation pathway. By inhibiting this step, it stops the formation of harmful downstream metabolites such as fumarylacetoacetate and succinylacetone, thereby protecting liver and renal tissue from damage.

The dose of nitisinone is individualized by the prescribing physician based on the patient’s age, weight, disease severity and laboratory monitoring. Dosage adjustments are made according to therapeutic response and safety parameters, and patients should follow the prescriber’s specific instructions.

Safety data for nitisinone during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It is generally recommended to avoid use in pregnant or nursing women unless the potential benefit outweighs the possible risk, and this decision should be made by a specialist.

To request Nitisinone Dipharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.

The primary alternative to nitisinone is liver transplantation, which removes the metabolic defect but carries surgical risk. Pharmacologically, nitisinone offers a non‑invasive, disease‑modifying approach by directly inhibiting the toxic pathway, allowing many patients to avoid or postpone transplantation while maintaining metabolic control.

Store the product at ambient temperature, preferably below 25 °C. Keep the tablets in their original blister pack or container, protect them from moisture, heat and direct sunlight. Do not refrigerate or freeze the medication, and keep it out of reach of children.

Nitisinone Dipharma is taken orally, usually with a glass of water. The exact timing (e.g., with or without food) and frequency are determined by the prescribing clinician based on individual therapeutic goals and tolerability.

Serious risks include elevated liver enzymes indicating hepatic stress, hypoglycaemia that may require glucose monitoring, peripheral neuropathy, severe skin reactions such as Stevens‑Johnson syndrome, and hematologic abnormalities like anemia or low platelet counts. Patients should report any unusual symptoms promptly.

Nitisinone should be avoided in individuals with known hypersensitivity to the drug or any HPPD inhibitor, in patients with severe hepatic impairment where monitoring is not feasible, and in pregnant or breastfeeding women unless a specialist determines that the benefits outweigh the risks.